NasdaqCM - Nasdaq Real Time Price USD

Zura Bio Limited (ZURA)

Compare

1.2100

+0.0900

+(8.04%)

At close: April 11 at 4:00:01 PM EDT

1.2500

+0.04

+(3.31%)

After hours: April 11 at 7:45:56 PM EDT

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

Insiders who bought US$1.01m worth of Zura Bio Limited ( NASDAQ:ZURA ) stock in the last year have seen some of their...

Simply Wall St. 18 days ago

ZURA
+8.04%
ZURAW
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

HENDERSON, Nev., March 25, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2024 financial results and recent corporate updates.

Business Wire 19 days ago

ZURA
+8.04%
ZURAW
Zura Bio to Present at the Leerink Partners Global Healthcare Conference

HENDERSON, Nev., February 24, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 p.m. ET, and will host investor meetings in Miami, FL.

Business Wire last month

ZURA
+8.04%
ZURAW
We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 2 months ago

ZURA
+8.04%
ZURAW
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

HENDERSON, Nev., December 23, 2024--Zura Bio launches TibuSURE, a Phase 2 global study evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in adults.

Business Wire 3 months ago

ZURA
+8.04%
ZURAW
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

HENDERSON, Nev., November 25, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 9:00 a.m. ET, and will host investor meetings in New York, NY.

Business Wire 4 months ago

ZURA
+8.04%
ZURAW
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

HENDERSON, Nev., November 14, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the submission of a protocol to its open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 2 study evaluating tibulizumab, a humanized tetravalent bispecific dual antagonist antibody designed to neutralize both IL-17

Business Wire 4 months ago

ZURA
+8.04%
ZURAW
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

HENDERSON, Nev., November 07, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates.

Business Wire 5 months ago

ZURA
+8.04%
ZURAW
Zura Bio to Participate in Two Upcoming Investor Conferences in November

HENDERSON, Nev., October 30, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in two investor conferences in November.

Business Wire 5 months ago

ZURA
+8.04%
ZURAW
Bullish Zura Bio Insiders Loaded Up On US$1.01m Of Stock

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Simply Wall St. 5 months ago

ZURA
+8.04%
ZURAW
Institutions profited after Zura Bio Limited's (NASDAQ:ZURA) market cap rose US$45m last week but private equity firms profited the most

Key Insights Zura Bio's significant private equity firms ownership suggests that the key decisions are influenced by...

Simply Wall St. 6 months ago

ZURA
+8.04%
ZURAW
Zura Bio to Present at Three Upcoming Investor Conferences in September

HENDERSON, Nev., September 03, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will present at three upcoming investor conferences in September.

Business Wire 7 months ago

ZURA
+8.04%
ZURAW
We're Not Very Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 7 months ago

ZURA
+8.04%
ZURAW
Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

HENDERSON, Nev., August 13, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its second quarter 2024 financial results, and recent business highlights.

Business Wire 7 months ago

ZURA
+8.04%
ZURAW
Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

HENDERSON, Nev., August 12, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has completed its previously announced exchange offer (the "Exchange Offer") and consent solicitation (the "Consent Solicitation") relating to its outstanding (i) public warrants that were issued in connection with its initial public offering to purchase Class

Business Wire 7 months ago

ZURA
+8.04%
ZURAW
Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

HENDERSON, Nev., August 09, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the expiration and results of its previously announced exchange offer (the "Exchange Offer") and consent solicitation (the "Consent Solicitation") relating to its outstanding (i) public warrants that were issued in connection with its initial public offering to purcha

Business Wire 7 months ago

ZURA
+8.04%
ZURAW
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024. “We are thrilled to welcome Anne and Jennifer to our boar

GlobeNewswire 8 months ago

BRNS

ZURA
+8.04%
ZURAW
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

HENDERSON, Nev., July 12, 2024--Zura Bio Limited (NASDAQ: ZURA) ("Zura Bio" or the "Company"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has commenced an exchange offer (the "Offer") and consent solicitation (the "Consent Solicitation") relating to its outstanding (i) public warrants that were issued in connection with its initial public offering to purchase Class A ordinary shares of the Company

Business Wire 8 months ago

ZURA
+8.04%
ZURAW
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

HENDERSON, Nev., June 14, 2024--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today shared supportive data from a Phase 1 study evaluating its lead candidate, tibulizumab (ZB-106), for the treatment of Sjogren’s syndrome. These data, along with preclinical data supporting further development of tibulizumab in rheumatoid arthritis (RA), were presented at the Annual European Congr

Business Wire 9 months ago

ZURA
+8.04%
ZURAW
Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

HENDERSON, Nev., June 06, 2024--Zura Bio Forms Scientific Advisory Board with Prominent Specialists

Business Wire 10 months ago

ZURA
+8.04%
ZURAW

Performance Overview

Return	ZURA	S&P 500 (^GSPC)
YTD	-51.60%	-8.81%
1-Year	-57.84%	+3.16%
3-Year	-84.76%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Zura Bio Limited (ZURA)

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Zura Bio to Participate in Two Upcoming Investor Conferences in November

Bullish Zura Bio Insiders Loaded Up On US$1.01m Of Stock

Institutions profited after Zura Bio Limited's (NASDAQ:ZURA) market cap rose US$45m last week but private equity firms profited the most

Zura Bio to Present at Three Upcoming Investor Conferences in September

We're Not Very Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Rate

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

Performance Overview